ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
High-Performance Prevascularized SHED-Laden rGO@Hydrogel Achieves Optimized Diabetic Bone Defect Repair.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Naringin-based hydrogel decorated 3D printed scaffold modulates immunity and angiogenesis for diabetic bone regeneration.Regenerative biomaterials · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Diabetic bone defects repair is severely hindered by impaired angiogenesis and delayed osteogenesis. Conventional tissue-engineered scaffolds often fail to achieve effective vascularization due to the compromised angiogenic capacity of host endothelial cells in the hyperglycemic microenvironment. Here, we developed a prevascularized scaffold by encapsulating stem cells from human exfoliated deciduous teeth (SHED), which shared developmental origin to craniofacial bone, within a reduced graphene oxide (rGO)-integrated hydrogel. rGO significantly accelerated SHED-mediated formation of vascular networks in vitro. The scaffold's therapeutic efficacy was confirmed in a clinically relevant diabetic beagle dog mandibular defect model, which showed increased vascular density and accelerated bone regeneration. Mechanistic validation revealed that rGO activates the FAK-Src/RELA pathway to upregulate P4HA1, subsequently enhancing collagen I synthesis and driving extracellular matrix (ECM) remodeling to create a pro-angiogenic niche. This study demonstrates that engineering the ECM with rGO is a novel strategy to accelerate prevascularization and bone repair in diabetic conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.